PT - JOURNAL ARTICLE AU - H. E. Taylor AU - C. F. Ackman AU - I. Horowitz TI - Canadian clinical trial of antilymphocyte globulin in human cadaver renal transplantation DP - 1976 Dec 18 TA - Canadian Medical Association Journal PG - 1205--1208 VI - 115 IP - 12 4099 - http://www.cmaj.ca/content/115/12/1205.short 4100 - http://www.cmaj.ca/content/115/12/1205.full SO - CMAJ1976 Dec 18; 115 AB - A multicentre, randomized clinical trial of antilymphocyte globulin (ALG) was conducted among patients who had undergone cadaver kidney transplantation; follow-up was continued for a minimum of 1 year. Of the 179 patients 92 were given conventional treatment only, while 87 were given in addition ALG (from a standardized, highly immunosuppressive, common pool of equine ALG), 20 mg/kg-d intravenously for 10 days after transplantation. The ALG-treated group had better accumulated graft survival, fewer nephrectomies, better graft function, less than half the number of acute rejection episodes and less prednisone use. There was a beneficial drug (ALG)-related effect in both the graft and the host during the first 3 months after transplantation.